Table of Contents Author Guidelines Submit a Manuscript
Journal of Toxicology
Volume 2014, Article ID 145325, 6 pages
http://dx.doi.org/10.1155/2014/145325
Review Article

Cyclosporine and Herbal Supplement Interactions

1Novartis Farma S.p.A., Origgio, Varese, Italy
2Marchesi Hospital, Inzago, Milan, Italy
3Department of Pathophysiology and Transplantation, University of Milan, I.R.C.C.S. Foundation, Cà Granda Ospedale Maggiore Policlinico, Milan, Italy

Received 19 July 2013; Revised 21 October 2013; Accepted 22 October 2013; Published 12 January 2014

Academic Editor: Steven J. Bursian

Copyright © 2014 D. Colombo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. F. Borel, “Comparative study of in vitro and in vivo drug effects on cell mediated cytotoxicity,” Immunological Communications, vol. 31, no. 4, pp. 631–641, 1976. View at Google Scholar · View at Scopus
  2. T. Kronbach, V. Fischer, and U. A. Meyer, “Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs,” Clinical Pharmacology and Therapeutics, vol. 43, no. 6, pp. 630–635, 1988. View at Google Scholar · View at Scopus
  3. D. Leveque and F. Jehl, “P-glycoprotein and pharmacokinetics,” Anticancer Research, vol. 15, no. 2, pp. 331–336, 1995. View at Google Scholar · View at Scopus
  4. V. J. Wacher, C.-Y. Wu, and L. Z. Benet, “Overlapping substrate specificities and tissue distribution of cytochrome p450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy,” Molecular Carcinogenesis, vol. 13, no. 3, pp. 129–134, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. R. S. Gaston, “Maintenance immunosuppression in the renal transplant recipient: an overview,” American Journal of Kidney Diseases, vol. 38, no. 6, supplement 6, pp. S25–S35, 2001. View at Google Scholar · View at Scopus
  6. Y. M. Di, C. G. Li, C. C. Xue, and S. Zhou, “Clinical drugs that interact with St. John's wort and implication in drug development,” Current Pharmaceutical Design, vol. 14, no. 17, pp. 1723–1742, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Wentworth, M. Agostini, J. Love, J. W. Schwabe, and V. K. K. Chatterjee, “St John's wort, a herbal antidepressant, activates the steroid X receptor,” Journal of Endocrinology, vol. 166, no. 3, pp. R11–R16, 2000. View at Google Scholar · View at Scopus
  8. S. Bauer, E. Störmer, A. Johne et al., “Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients,” British Journal of Clinical Pharmacology, vol. 55, no. 2, pp. 203–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. W. Barone, B. J. Gurley, B. L. Ketel, and S. R. Abul-Ezz, “Herbal supplements: a potential for drug interactions in transplant recipients,” Transplantation, vol. 71, no. 2, pp. 239–241, 2001. View at Google Scholar · View at Scopus
  10. C. Moschella and B. L. Jaber, “Interaction between cyclosporine and Hypericum perforatum (St. John's Wort) after organ transplantation,” American Journal of Kidney Diseases, vol. 38, no. 5, pp. 1105–1107, 2001. View at Google Scholar · View at Scopus
  11. D. G. Bailey, J. D. Spence, B. Edgar, C. D. Bayliff, and J. M. O. Arnold, “Ethanol enhances the hemodynamic effects of felodipine,” Clinical and Investigative Medicine, vol. 12, no. 6, pp. 357–362, 1989. View at Google Scholar · View at Scopus
  12. P. Schmiedlin-Ren, D. J. Edwards, M. E. Fitzsimmons et al., “Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins,” Drug Metabolism and Disposition, vol. 25, no. 11, pp. 1228–1233, 1997. View at Google Scholar · View at Scopus
  13. M. P. Ducharme, L. H. Warbasse, and D. J. Edwards, “Disposition of intravenous and oral cyclosporine after administration with grapefruit juice,” Clinical Pharmacology and Therapeutics, vol. 57, no. 5, pp. 485–491, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. L. L. Ioannides-Demos, N. Christophidis, P. Ryan, P. Angelis, L. Liolios, and A. J. McLean, “Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases,” Journal of Rheumatology, vol. 24, no. 1, pp. 49–54, 1997. View at Google Scholar · View at Scopus
  15. G. C. Yee, D. L. Stanley, L. J. Pessa et al., “Effect of grapefruit juice on blood cyclosporin concentration,” The Lancet, vol. 345, no. 8955, pp. 955–956, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. D. I. Min, Y. Ku, P. J. Perry et al., “Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients,” Transplantation, vol. 62, no. 1, pp. 123–125, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. Brunner, K. Pai, M. Y. Munar, M. B. Lande, A. J. Olyaei, and J. A. Mowry, “Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients,” Pediatric Transplantation, vol. 4, no. 4, pp. 313–321, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Chiang, P. L. Chao, S. Hsiu, K. Wen, S. Tsai, and Y. Hou, “Ginger significantly decreased the oral bioavailability of cyclosporine in rats,” American Journal of Chinese Medicine, vol. 34, no. 5, pp. 845–855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. A. W. Zuardi, “Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action,” Revista Brasileira de Psiquiatria, vol. 30, no. 3, pp. 271–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Jaeger, L. Z. Benet, and L. M. Bornheim, “Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes,” Xenobiotica, vol. 26, no. 3, pp. 275–284, 1996. View at Google Scholar · View at Scopus
  21. J. W. Budzinski, B. C. Foster, S. Vandenhoek, and J. T. Arnason, “An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures,” Phytomedicine, vol. 7, no. 4, pp. 273–282, 2000. View at Google Scholar · View at Scopus
  22. L. H. Goldstein, M. Elias, G. Ron-Avraham et al., “Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards,” British Journal of Clinical Pharmacology, vol. 64, no. 3, pp. 373–380, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Nowack and B. Nowak, “Herbal teas interfere with cyclosporin levels in renal transplant patients,” Nephrology Dialysis Transplantation, vol. 20, no. 11, pp. 2554–2556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. C. Hou, S. P. Lin, and P. D. Chao, “Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A,” Food Chemistry, vol. 135, no. 4, pp. 2307–2312, 2012. View at Google Scholar
  25. B. Huang, G. Li, F. Ren et al., “Effect of Glycyrrhiza inflata and Daphne genkwa on permeabilities of rhodamine 123, a P-glycoprotein substrate across rat jejunum membranes in vitro,” Zhongguo Zhongyao Zazhi, vol. 33, no. 21, pp. 2521–2526, 2008. View at Google Scholar · View at Scopus
  26. N. Yoshida, M. Koizumi, I. Adachi, and J. Kawakami, “Inhibition of P-glycoprotein-mediated transport by terpenoids contained in herbal medicines and natural products,” Food and Chemical Toxicology, vol. 44, no. 12, pp. 2033–2039, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Lai, S. Hsiu, Y. Hou, S. Tsai, and P. L. Chao, “Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis,” Planta Medica, vol. 70, no. 2, pp. 132–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Wang, P. L. Chao, S. Hsiu, K. Wen, and Y. Hou, “Lethal quercetin-digoxin interaction in pigs,” Life Sciences, vol. 74, no. 10, pp. 1191–1197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Y. Yang, P. D. L. Chao, Y. C. Hou, S. Y. Tsai, K. C. Wen, and S. L. Hsiu, “Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats,” Food and Chemical Toxicology, vol. 44, no. 9, pp. 1572–1578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Hsiu, Y. Hou, Y. Wang, C. Tsao, S. Su, and P. L. Chao, “Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats,” Life Sciences, vol. 72, no. 3, pp. 227–235, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Yu, P. Wu, Y. Hou et al., “Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4644–4648, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. H. Yale and I. Glurich, “Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9,” Journal of Alternative and Complementary Medicine, vol. 11, no. 3, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. P. W. Hsu, C. S. Shia, S. P. Lin et al., “Potential risk of mulberry-drug interaction: modulation on P-glycoprotein and cytochrome P450 3A,” Journal of Agricultural and Food Chemistry, vol. 61, no. 18, pp. 4464–4469, 2013. View at Google Scholar
  34. Z. Mostafavi-pour, F. Zal, A. Monabati, and M. Vessal, “Protective effects of a combination of quercetin and vitamin E against cyclosporine A-induced oxidative stress and hepatotoxicity in rats,” Hepatology Research, vol. 38, no. 4, pp. 385–392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Zal, Z. Mostafavi-Pour, and M. Vessal, “Comparison of the effects of vitamin E and/or quercetin in attenuating chronic cyclosporine A-induced nephrotoxicity in male rats,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 8, pp. 720–724, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. S. V. Satyanarayana, D. Singh, and K. Chopra, “Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 23, no. 4, pp. 175–181, 2001. View at Google Scholar · View at Scopus
  37. G. Regev-Shoshani, O. Shoseyov, and Z. Kerem, “Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4,” Biochemical and Biophysical Research Communications, vol. 323, no. 2, pp. 668–673, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Yu, S. Wu, M. Zhang, and C. Pan, “Effect of resveratrol alone and its combination with cyclosporin A on the immune function of human peripheral blood T lymphocytes,” Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, vol. 19, no. 6, pp. 549–551, 2003. View at Google Scholar · View at Scopus
  39. V. Chander, N. Tirkey, and K. Chopra, “Resveratrol, a polyphenolic phytoalexin protects against cyclosporine-induced nephrotoxicity through nitric oxide dependent mechanism,” Toxicology, vol. 210, no. 1, pp. 55–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Yang, S. Tsai, Y. Hou, and P. L. Chao, “Inductive modulation on P-glycoprotein and cytochrome 3A by resveratrol, a constituent of grapes,” Food Chemistry, vol. 133, no. 3, pp. 683–688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Tacklind, R. MacDonald, I. Rutks, and T. J. Wilt, “Serenoa repens for benign prostatic hyperplasia,” Cochrane Database of Systematic Reviews, no. 12, Article ID CD001423, 2012. View at Google Scholar · View at Scopus
  42. J. S. Markowitz, J. L. Donovan, C. L. DeVane et al., “Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers,” Clinical Pharmacology and Therapeutics, vol. 74, no. 6, pp. 536–542, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. J. C. Gorski, S. Huang, A. Pinto et al., “The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo,” Clinical Pharmacology and Therapeutics, vol. 75, no. 1, pp. 89–100, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. B. J. Gurley, S. F. Gardner, M. A. Hubbard, D. K. Williams, W. B. Gentry, and J. Carrier, “In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto,” Clinical Pharmacology and Therapeutics, vol. 76, no. 5, pp. 428–440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. H.-W. Xin, X.-C. Wu, Q. Li, A.-R. Yu, M.-Y. Zhong, and Y.-Y. Liu, “The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 1, pp. 25–29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. X. Wu, Q. Li, H. Xin, A. Yu, and M. Zhong, “Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study,” European Journal of Clinical Pharmacology, vol. 61, no. 8, pp. 567–572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Pan, G. Wang, X. Liu, J. P. Fawcett, and Y. Xie, “The involvement of P-glycoprotein in berberine absorption,” Pharmacology and Toxicology, vol. 91, no. 4, pp. 193–197, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Qiu, X. H. Jiang, C. X. Liu, Y. Ju, and J. X. Jin, “Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp,” Phytotherapy Research, vol. 23, no. 11, pp. 1553–1558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Tsai and T. Tsai, “Hepatobiliary excretion of berberine,” Drug Metabolism and Disposition, vol. 32, no. 4, pp. 405–412, 2004. View at Publisher · View at Google Scholar · View at Scopus